Zoetis has been granted a patent for recombinant viral vectors designed for safe immunizations against various pathogens. The invention includes multivalent vaccine compositions and methods for creating and utilizing these vectors. One claim involves a recombinant Herpesvirus of Turkey genome with specific heterologous antigen insertions. GlobalData’s report on Zoetis gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Zoetis, Personalized cancer vaccines was a key innovation area identified from patents. Zoetis's grant share as of January 2024 was 54%. Grant share is based on the ratio of number of grants to total number of patents.
Recombinant viral vectors for multivalent pathogen protection in vaccines
A recently granted patent (Publication Number: US11883481B2) discloses a recombinant Herpesvirus of Turkey (HVT) genome designed for avian disease prevention. The genome includes nucleotide sequences encoding heterologous antigens from Infectious Bursal Disease Virus and Newcastle Disease Virus inserted at specific loci within the HVT genome. The antigens include VP2, VP3, and VP4 proteins from Infectious Bursal Disease Virus, and F/HN chimera, F, NP, P, M, HN, and L proteins from Newcastle Disease Virus.
Furthermore, the patent covers the inclusion of promoters such as immediate early cytomegalovirus human (hCMV) promoter, murine immediate early CMV promoter, and poly A signals like SV40 poly A tail and Bovine Growth Hormone (BGH) poly A tail within the recombinant HVT genome. The patent also extends to vaccine compositions, cell lines producing the recombinant virus, and methods of preventing Infectious Bursal Disease, Newcastle Disease, and Marek's Disease in avians by administering the vaccine through various routes like spray, in ovo, subcutaneous, intramuscular, oral, or nasal administration, providing a comprehensive approach to avian disease prevention.
To know more about GlobalData’s detailed insights on Zoetis, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
